Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02758717
Title Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Academic and Community Cancer Research United
Indications

Hodgkin's lymphoma

Therapies

Brentuximab vedotin + Nivolumab

Age Groups: senior | adult | child
Covered Countries USA


No variant requirements are available.